Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis

June D Cody; Elisabeth M Hodson

doi:10.1002/14651858.CD003266.pub3

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Respuestas clínicas Cochrane
Guías
Temas

Revisiones y protocolos relacionados

Respuestas clínicas Cochrane

Topics

Temas

Figure 1

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
The empty rows relate to abstract‐only publications ‐ risk of bias could not be assessed

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.1

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 1 Number starting RRT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 2 GFR.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 3 Reduction in GFR.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 4 Serum creatinine.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 5 Increase in serum creatinine.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.6

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 6 Haemoglobin.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.7

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 7 Haematocrit.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.8

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 8 Number of patients transfused.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.9

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 9 Quality of life measures.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.10

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 10 Change in exercise capacity.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.11

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 11 Systolic blood pressure.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.12

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 12 Diastolic blood pressure.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.13

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 13 Number with an increase or introduction of antihypertensive treatment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.14

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 14 Number discontinued due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.15

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 15 Seizures.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.16

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 16 Mortality.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1. rHuEPO versus placebo or no rHuEPO

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number starting RRT Show forest plot	6		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only

1.1 Starting RRT during the study period	5	207	Risk Ratio (M‐H, Random, 95% CI)	0.70 [0.43, 1.14]
1.2 Starting RRT in the follow‐up to the study	1	8	Risk Ratio (M‐H, Random, 95% CI)	3.0 [0.50, 17.95]
2 GFR Show forest plot	7	283	Mean Difference (IV, Random, 95% CI)	‐2.11 [‐3.08, ‐1.15]

3 Reduction in GFR Show forest plot	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

4 Serum creatinine Show forest plot	8	327	Mean Difference (IV, Random, 95% CI)	27.86 [‐32.04, 87.76]

5 Increase in serum creatinine Show forest plot	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

6 Haemoglobin Show forest plot	4	237	Mean Difference (IV, Random, 95% CI)	‐1.90 [‐2.34, ‐1.47]

7 Haematocrit Show forest plot	7	145	Mean Difference (IV, Random, 95% CI)	‐9.85 [‐11.34, ‐8.35]

8 Number of patients transfused Show forest plot	3	111	Risk Ratio (M‐H, Random, 95% CI)	0.32 [0.12, 0.83]

9 Quality of life measures Show forest plot	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

10 Change in exercise capacity Show forest plot	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

11 Systolic blood pressure Show forest plot	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

12 Diastolic blood pressure Show forest plot	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

13 Number with an increase or introduction of antihypertensive treatment Show forest plot	4	232	Risk Ratio (M‐H, Random, 95% CI)	1.26 [0.76, 2.11]

14 Number discontinued due to adverse events Show forest plot	4	223	Risk Ratio (M‐H, Random, 95% CI)	0.86 [0.28, 2.59]

15 Seizures Show forest plot	3	140	Risk Ratio (M‐H, Random, 95% CI)	0.22 [0.02, 1.94]

16 Mortality Show forest plot	4	182	Risk Ratio (M‐H, Random, 95% CI)	0.60 [0.13, 2.88]

Comparison 1. rHuEPO versus placebo or no rHuEPO

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet